LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Holdings Boosted by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,440 shares of the medical instruments supplier’s stock after buying an additional 315 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in LeMaitre Vascular were worth $317,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. New York State Teachers Retirement System grew its holdings in LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after acquiring an additional 100 shares during the period. Flputnam Investment Management Co. boosted its position in shares of LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC grew its stake in shares of LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after purchasing an additional 103 shares during the last quarter. Blue Barn Wealth LLC raised its holdings in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its stake in LeMaitre Vascular by 0.8% during the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Lake Street Capital upped their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.25.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $83.92 on Friday. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of 45.86, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The company has a 50 day simple moving average of $93.39 and a 200-day simple moving average of $94.34. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. On average, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.95%. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.